Acorda Launches Alexa Skill in Conjunction with MS Awareness Month
March 13 2017 - 7:00AM
Business Wire
Launch is part of a variety of activities
supporting the MS community during MS Awareness Month
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the
launch of its Alexa skill, MS Awareness Facts, as part of the company’s activities in
recognition of Multiple Sclerosis (MS) Awareness Month. The skill
allows users to ask Amazon Alexa for an MS Awareness Fact to learn
more about multiple sclerosis and find helpful information on MS
and its symptoms.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170313005298/en/
Amazon Alexa is Amazon’s cloud-based voice service. Using voice
commands, users interact with Alexa, asking her for what they want,
in this case, “Alexa, start MS Awareness.” Alexa will randomly
select from one of almost 50 tips and facts about MS, and read it
aloud to the user.
“We’re proud to be at the forefront of using this new technology
to connect with patients,” said Michael Russo, Executive Director,
Corporate Digital Strategy & Innovation. “Education is an
important component of each person’s fight against multiple
sclerosis. As we move towards becoming an increasingly digital
society, it’s important that we provide solutions that match the
way people live and work, and in this case that means voice
search.”
The MS Awareness Facts skill leverages content from the
company’s award-winning MS self™ app. In addition to the skill,
Acorda has also created a team on Charity Miles, a free app for
Android or iPhone. Charity Miles allows users to raise money for
charity by walking, running, or biking. Users can download the app
and join Acorda’s team by searching for #MSAwareness; Acorda team
members may elect an MS charity as the recipient of funds
raised.
About MS Awareness Month
Throughout the month of March, advocacy organizations such as
the National MS Society, the MS Association of America, the MS
Foundation campaign to expand knowledge, understanding and support
of multiple sclerosis.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, usually progressive
disease in which the immune system attacks and degrades the
function of nerve fibers in the brain and spinal cord by destroying
myelin (a process known as demyelination) and eventually the nerve
fibers themselves. Myelin is a fatty layer of membranes that
insulates nerves, facilitating the transmission of electrical
impulses through nerve pathways that control all neurological
functions. In people with MS, disruption in neurological function
often leads to impairments in movement, bowel/bladder function,
vision and sexual function. More than 400,000 people in the U.S.
and nearly 2.5 million people worldwide are living with MS.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company
focused on developing therapies that restore function and improve
the lives of people with neurological disorders.
Acorda has an industry leading pipeline of novel neurological
therapies addressing a range of disorders, including Parkinson’s
disease, migraine and multiple sclerosis. Acorda markets three
FDA-approved therapies, including AMPYRA® (dalfampridine) Extended
Release Tablets, 10 mg.Acorda, Acorda Therapeutics, Ampyra and MS
Self are registered trademarks of Acorda Therapeutics Inc.
For more information, please visit the Company’s website at:
www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other
reasons because acquired development programs are generally subject
to all the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the ability to successfully integrate
Biotie’s operations and Civitas’ operations, respectively, into our
operations; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301 or any other acquired or
in-licensed programs; we may not be able to complete development
of, obtain regulatory approval for, or successfully market CVT-301,
any other products under development, or the products that we will
acquire when we complete the Biotie transaction; the occurrence of
adverse safety events with our products; delays in obtaining or
failure to obtain and maintain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaborator Biogen in connection therewith; competition;
failure to protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third party
intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements
could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170313005298/en/
Acorda Therapeutics, Inc.Jeff Macdonald, (914)
326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024